We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Ticker | Name | Price | Change | Change % | Volume |
---|---|---|---|---|---|
HOVR | New Horizon Aircraft Ltd | 1.38 | 0.66 | 91.67% | 2,775,187 |
SPEC | Spectaire Holdings Inc | 0.765 | 0.33655 | 78.55% | 12,230,598 |
LGHLW | Lion Group Holding Ltd | 0.0035 | 0.0007 | 25.00% | 177,553 |
AYRO | AYRO Inc | 0.9899 | 0.1603 | 19.32% | 109,144 |
NISN | NiSun International Enterprise Development Group Company Ltd | 4.02 | 0.65 | 19.29% | 351,364 |
RNAZ | TransCode Therapeutics Inc | 1.27 | 0.17 | 15.45% | 47,774 |
PRST | Presto Technologies Inc | 0.1027 | 0.0136 | 15.26% | 15,724,684 |
SVRE | SaverOne 2014 Ltd | 0.595 | 0.075 | 14.42% | 1,228 |
RVYL | RYVYL Inc | 1.61 | 0.18 | 12.59% | 10,510 |
MCRB | Seres Therapeutics Inc | 0.6837 | 0.0697 | 11.35% | 96,593 |
NKTR | Nektar Therapeutics | 1.40 | 0.14 | 11.11% | 8,307 |
SHANGHAI, June 7, 2024 /PRNewswire/ -- Nisun International Enterprise Development Group Co., Ltd ("Nisun International" or the "Company") (Nasdaq: NISN), a technology and industry driven integrated supply chain solutions provider, today announced that it has achieved a significant breakthrough in its egg business following the Company stepping into the egg industry.
Transaction ensures Nestlé Health Science will continue to commercialize the product BRIDGEWATER, N.J., June 6, 2024 /PRNewswire/ -- Seres Therapeutics, Inc. (Nasdaq: MCRB), announced today that it has agreed to a non-binding memorandum of understanding with Nestlé Health Science in which Nestlé Health Science will acquire certain tangible and intangible assets associated with VOWST (fecal microbiota spores, live-brpk) capsules. This transaction, when completed, supersedes any prior agreements between Nestlé and Seres concerning VOWST. Nestlé Health Science has been the lead commercialization party for the product since its launch in June 2023 in the United States. This transaction will allow Nestlé Health Science ...
ROCKVILLE, Md., June 6, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced the appointment of Dr. Phillip Dennis as Chief Medical Officer. Dr. Dennis, who will join I-Mab effective June 17, 2024, will lead the Company's global clinical development efforts and serve as a member of I-Mab's Executive Leadership Team.
iHeartMedia today announced the lineup for the 2024 iHeartRadio Music Festival presented by Capital One, the annual concert event taking place on Friday, Sept. 20 and Saturday, Sept. 21 at T-Mobile Arena. This year, the epic two-day lineup for the iHeartRadio Music Festival presented by Capital One will feature performances by Big Sean, Camila Cabello, Doja Cat, Gwen Stefani, Hozier, Keith Urban, New Kids on the Block, Paramore, Shaboozey, The Black Crowes, Thomas Rhett, Victoria Monét and more. Hosted by Ryan Seacrest, the iHeartRadio Music Festival will once again include one-of-a-kind collaborations and surprise performances.
Ticker | Name | Price | Change | Change % | Market Cap | Volume |
---|---|---|---|---|---|---|
BTC | Bitcoin | 69,322.86 | -1,437.89 | -2.03% | 1.36T | 5,089,995,367 |
ETH | Ethereum | 3,685.59 | -125.68 | -3.30% | 443B | 2,673,202,988 |
BNB | Binance Coin | 683.81 | -26.66 | -3.75% | 107.9B | 523,395,468 |
USDT | Tether USD | 0.99962 | 0.00001 | 0.00% | 97.8B | 274,992,819 |
SOL | Solana | 162.43 | -7.52 | -4.42% | 71.62B | 1,121,122,189 |
STETH | stETH | 3,685.78 | -123.20 | -3.23% | 35.99B | 13,461,977 |
USDC | USD Coin | 0.9999 | 0.0001 | 0.01% | 28.07B | 1,001,764,065 |
XRP | Ripple | 0.4989 | -0.0225 | -4.32% | 27.22B | 449,534,168 |
TONCOIN | Wrapped TON Coin | 7.27 | -0.226196 | -3.02% | 25.07B | 227,431,331 |
DOGE | Dogecoin | 0.14827 | -0.01176 | -7.35% | 21.22B | 433,788,388 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions